FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma<br>
FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Share FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

Sign up to save your podcasts

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript